Published on 02/12/2021

Clinical study on Covid-19 - End of recruitment

📣 Artialis is pleased to announce the end of recruitment of its first clinical study on COVID-19 (CHOPIN with Nasafytol). In this comparative randomized clinical trial, patients received NASAFYTOL (curcumin and quercetin) as a nutritional support to the standard treatment of hospitalized patients infected with COVID-19. 

➡ More information on
Identifier : NCT04844658

We thank the Sponsor for its trust toward Artialis’ services.

Artialis, a leader CRO located in Belgium has demonstrated that it can ensure fast recruitment in infectious disease.



 © Artialis - All rights reserved
Terms & conditions - Privacy Policy